Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akela Pharma, a drug development company focused on developing therapies for the inhalation and pain markets, has announced the resignation of Maurice St-Jacques from the board of directors.
Subscribe to our email newsletter
The company has also announced the nomination of John Dempsey to its board. Halvor Jaeger resigned as CEO, but remains member of the board of directors to be able to concentrate as special envoy of the board on financing, mergers and acquisitions.
Furthermore, Andrew Reiter, the company’s current COO and CFO will from now on be responsible for all operational activities at PharmaForm, Akela’s Austin based wholly owned subsidiary. Taneli Jouhikainen, the company’s current senior vice-president of corporate development will from now on be responsible for all product development programs at Akela Pharma.
The board of directors of Akela Pharma is currently evaluating different options regarding an eventual CEO replacement.
Gunter Knorr, chairman of the board of Akela Pharma, said: “On behalf of the board of directors and employees of Akela Pharma, I would like to take this opportunity to thank Dr Jaeger and Dr St-Jacques for their relentless efforts in establishing Akela Pharma as a leader in the field of inhalation and pain therapies.
“Their contributions have served to establish a solid base from which the company will be able to build upon in the years to come. I also wish to welcome Mr Dempsey to board of directors as we all look forward to working with him and benefit from his extensive experience.”